Last reviewed · How we verify
CSII+Vildagliptin
CSII (continuous subcutaneous insulin infusion) combined with vildagliptin, a DPP-4 inhibitor, delivers insulin continuously while enhancing endogenous insulin secretion by inhibiting dipeptidyl peptidase-4.
CSII (continuous subcutaneous insulin infusion) combined with vildagliptin, a DPP-4 inhibitor, delivers insulin continuously while enhancing endogenous insulin secretion by inhibiting dipeptidyl peptidase-4. Used for Type 2 diabetes mellitus (in combination with continuous subcutaneous insulin infusion).
At a glance
| Generic name | CSII+Vildagliptin |
|---|---|
| Sponsor | The First Affiliated Hospital of Xiamen University |
| Drug class | DPP-4 inhibitor (combined with insulin therapy) |
| Target | DPP-4 (dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Vildagliptin inhibits DPP-4, an enzyme that degrades incretin hormones (GLP-1 and GIP), thereby prolonging their action to stimulate glucose-dependent insulin secretion and suppress glucagon. When combined with CSII (insulin pump therapy), this dual approach provides both exogenous insulin delivery and enhanced endogenous insulin secretion, improving glycemic control in type 2 diabetes patients.
Approved indications
- Type 2 diabetes mellitus (in combination with continuous subcutaneous insulin infusion)
Common side effects
- Hypoglycemia
- Nasopharyngitis
- Headache
- Upper respiratory tract infection
Key clinical trials
- Effects of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification (PHASE4)
- Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CSII+Vildagliptin CI brief — competitive landscape report
- CSII+Vildagliptin updates RSS · CI watch RSS
- The First Affiliated Hospital of Xiamen University portfolio CI